Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

全面介紹

書目詳細資料

Principais autores:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
格式:	Artigo
語言:	Inglês
出版:	Wiley 2020-07-01
叢編:	Endocrinology, Diabetes & Metabolism
主題:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
在線閱讀:	https://doi.org/10.1002/edm2.159
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!